Targeted Treatment: The Role of Injectables in Weight Loss Management
Target Audience: Pharmacy Tech
Course Overview
Injectable antiobesity medications (AOMs) offer a novel approach to obesity management by targeting neurohormonal pathways to achieve sustained weight loss and improve metabolic health. Agents like liraglutide, semaglutide, and tirzepatide have demonstrated significant efficacy in clinical trials, with benefits including cardiometabolic risk reduction and treatment of sleep apnea. Incorporating AOMs into a comprehensive treatment plan that includes dietary, physical, and behavioral interventions is essential for optimizing outcomes. This educational activity will explore the mechanisms, efficacy, and safety profiles of injectable AOMs, emphasizing their integration into a comprehensive obesity treatment framework. This course will also discuss the role of interprofessional collaboration in delivering patient-centered obesity care for patients utilizing these medications.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Compare and Contrast available injectable anti-obesity medications (AOMs)
- Evaluate the efficacy and safety of injectable AOMs
- Describe how to incorporate injectable therapies into comprehensive weight loss plans
- Counsel patients on the use of injectable AOMs
Faculty
I. Introduction
II. A Paradigm Shift in Treatment Guidelines for Obesity
III. Pharmacotherapy Treatment Guidelines for Obesity
IV. Nutrient-Stimulated Anti-Obesity Medications
A. Liraglutide
B. Semaglutide
C. Tirzepatide
V. Considerations for Use of Nutrient-Stimulated AOMs
VI. Patient Counseling Considerations
A. Injection Technique
B. Storage
C. Cost Considerations
D. Compounding Concerns
VII. MC4 Receptor Agonists: Setmelanotide
VIII. Considerations for the Healthcare Team
IX. Summary
From May 12, 2025 through May 12, 2028, participants must:
- Read the "learning objectives" and "author and planning team disclosures"
- Study the section entitled "educational activity"
- Complete the Course Test and Evaluation form. The Course Test will be graded automatically. Following successful completion of the Course Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
Credit for this course will be automatically uploaded to CPE Monitor®.
Faculty Planner Disclosure
The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP, Liz Fredrickson, PharmD, BCPS, Susan Bowlin, DNP, FNP-BC, ACNP-BC, CBN, and Pamela Sardo, PharmD, BS. Austin Frederickson, Liz Frederickson, and Pamela Sardo have no conflict of interest or financial relationship or commercial or financial support relevant to this activity to report or disclose in the development of this activity. Susan Bowlin is a member of the Speaker’s Bureau for Eli Lilly and Novo Nordisk. Any potential conflicts of interest were mitigated.
Unlabeled Use Disclosure
The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.
Please ensure the device you plan to use meets these requirements:
- Operating System: Windows 7, 8, 10, or 11 / Mac OS X 10.9 or later / iOS / Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
Accreditation
In support of improving patient care, RxCE.com is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PTCB Recognition
RxCe.com, LLC, offers pharmacy technician continuing education courses for PTCB recertification. Pharmacy technician courses are indicated both in the Target Audience description and the ACPE UAN which will end with a "T".